NABILONE

/static/temp/default.svg

Search structure


Trade Names	CESAMET
Synonyms	CPD 109514 CPD-109514 Cesamet Nabilone
Status
Molecule Category	UNKNOWN
ATC	A04AD11
UNII	2N4O9L084N


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	GECBBEABIDMGGL-UHFFFAOYSA-N
Smiles	CCCCCCC(C)(C)c1cc(O)c2c(c1)OC(C)(C)C1CCC(=O)CC21
InChI	InChI=1S/C24H36O3/c1-6-7-8-9-12-23(2,3)16-13-20(26)22-18-15-17(25)10-11-19(18)24(4,5)27-21(22)14-16/h13-14,18-19,26H,6-12,15H2,1-5H3

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C24H36O3
Molecular Weight	372.55
AlogP	6.26
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	6.0
Polar Surface Area	46.53
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	27.0

Bioactivity

Mechanism of Action	Action	Reference
Cannabinoid CB1 receptor agonist	AGONIST	DailyMed


Protein: Cannabinoid CB1 receptor Description: Cannabinoid receptor 1 Organism : Homo sapiens P21554 ENSG00000118432

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Membrane receptor Family A G protein-coupled receptor Small molecule receptor (family A GPCR) Lipid-like ligand receptor (family A GPCR) Cannabinoid receptor	16	-	-	4	-

Assay Description	Organism	Bioactivity	Reference
Displacement of [3H]-CP55940 from human CB2 receptor expressed in CHO cells by liquid scintillation counting	Homo sapiens	6.31 nM
Displacement of [3H]-CP55940 from human CB1 receptor expressed in CHO cells by liquid scintillation counting	Homo sapiens	3.981 nM
Agonist activity at human CB1 receptor expressed in CHO cells assessed as stimulation of [3H]-arachidonic acid release	Homo sapiens	3.981 nM
Agonist activity at human CB2 receptor expressed in CHO cells assessed as increase of forskolin-stimulated cAMP accumulation after 20 mins	Homo sapiens	15.85 nM

Related Entries

Cross References

Resources	Reference
ChEBI	135574
ChEMBL	CHEMBL2218896
DrugBank	DB00486
DrugCentral	1862
FDA SRS	2N4O9L084N
Guide to Pharmacology	9071
KEGG	D05099
PubChem	5284592
SureChEMBL	SCHEMBL563809
ZINC	ZINC01542930

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).